B&M: Sam, from a European perspective, what feels different this time from the previous IPO window? SF: I think the one thing that stands out specifically is the IPO of Circassia…
We all know that partnerships are the lifeblood of the biopharma industry. Understanding what makes them work can mean the difference between disaster and blockbuster success for biotech and pharma…
B&M: So David, let’s start by you just telling me a little bit about your VC firm, what is your history and your key focus? DG: Index was founded in 1996. In the…
We caught up with Dr Eliot Forster, CEO of Creabilis Therapeutics and the Executive Chair of MedCity to talk us through the last couple of months progress since the launch.…
B&M: Nigel you’re the Chief Investment Officer within Imperial Innovations and responsible for the Group’s investment activities, but what does that equate to on a day-to-day basis?…
What is keeping biotech CEOs awake at night? Terry O’Dwyer, Co-CEO, Biotech and Money: What is keeping you awake at night? Tim Mitchell, CEO, Sareum: The challenge is to…
Tapping the Markets An interview with Vectura’s CEO, Chris Blackwell In March this year Vectura, a product development company that focuses on the development of pharmaceutical therapies for the treatment…
The biopharma funding and investment climate definitely seems to have picked up for over the past year. Still, many biotech CEO’s fret about the dearth of opportunities – particularly for…
Removing the hype from IPO Dr Darrin Disley is President and CEO of Horizon Discovery. A life scientist with a track record of raising c$190 million in business financing from…
